Pfizer agreed in May 2025 to pay 3SBio $1.25 billion upfront for SSGJ-707. The same release named up to $4.8 billion in milestones. [1] The upfront is 20.7% of the $6.05 billion headline. That figure is our calculation, not a reported number.
BMS and BioNTech signed a larger deal a month later. BMS pays $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028, plus up to $7.6 billion in milestones. [2] The headline is $11.1 billion. The guaranteed part is $3.5 billion, or 31.5%.
Summit paid Akeso $500 million upfront in 2022 against a $5.0 billion headline. [3] That is 10.0%. Novartis paid BeiGene $650 million upfront in 2021 against about $2.2 billion in named payments. [4] That is 29.5%. Both deals show the same pattern. The number in the headline is mostly a conditional promise.
The Short Answer: What a Pharma Licensing Deal Pays and What It Does Not
A pharma licensing deal pays cash at signing, cash on defined events, and royalties on sales. In the four deals we reviewed, upfront cash was 10.0% to 29.5% of the headline value (analysis). The rest depends on trial results, approvals, and sales. Royalties also end when the licensed patent ends, under U.S. law. [21]
The Five Findings That Matter
Upfront payments were 10.0% to 29.5% of headline value across four documented licenses signed from 2021 to 2025 (analysis of [1], [2], [3], [4]).
BMS and BioNTech fixed 31.5% of the $11.1 billion headline as non-contingent cash: $1.5 billion upfront plus $2 billion in anniversary payments (analysis of [2]).
Three PD-1/PD-L1 plus VEGF bispecific licenses carry a combined headline of $22.15 billion. Their upfronts total $3.25 billion, or 14.7% (analysis of [1], [2], [3]).
If we risk-adjust the Pfizer-3SBio milestones with BIO phase data, expected value is about $1.98 billion, or 32.7% of the headline (illustrative analysis, undiscounted).
Novartis returned tislelizumab rights to BeiGene about 32 months after signing. BeiGene regained global rights with no royalty due to Novartis (analysis of [4], [15], [25]).
A royalty tied only to a patent cannot run past that patent. A hypothetical 15% royalty on $2.0 billion in annual sales loses $1.2 billion in nominal royalties over four post-expiry years (scenario analysis).
Methodology and Definitions: How We Built the Numbers
What Data Did We Analyze?
We used company press releases and SEC filings for four deals: Pfizer-3SBio (May 2025), BMS-BioNTech (June 2025), Summit-Akeso (December 2022), and Novartis-BeiGene (January 2021). [1][2][3][4] We selected deals with disclosed upfront and milestone figures from the parties themselves. We did not use deals where only press estimates exist.
How Did We Calculate the Derived Figures?
Headline value is upfront plus any non-contingent payments plus the maximum stated milestones. Upfront share is upfront divided by headline value. Guaranteed share adds non-contingent payments to the numerator. Equity components and undisclosed royalty rates are excluded. For the risk-adjusted scenarios, we used BIO phase-transition rates. [6][7]
Definitions Used in This Article
What Is a Biobuck?
A biobuck is a milestone payment counted in a headline deal value. The licensee pays it only if a defined event occurs. This is industry shorthand, not a legal term.
What Is a Non-Contingent Payment?
A non-contingent payment is due on a fixed date whatever the trial outcome. BMS owes BioNTech $2 billion of these through 2028. [2]
What Are All Commercially Significant Rights?
This is an FTC term. It means exclusive rights to a patent that allow only the recipient to use it in a therapeutic area or specific indication. [30]
What Are the Limits of This Analysis?
Four deals are not a market sample. Milestone schedules are mostly undisclosed. BIO rates are cross-indication averages. BIO reports lower LOA for oncology overall (5.3% from Phase I) and higher for immuno-oncology (12.4%). [16] Our scenarios show scale, not deal value.
Why Are Pharma Companies Licensing More Assets?
What Is the Patent Clock Behind the Demand?
Merck reported $31.68 billion in 2025 Keytruda and Keytruda Qlex sales. [12] Its compound patent expires in December 2028 and a method patent in May 2029. [12] Phase I to approval takes about 10.5 years on average. [16] A company with a 2028 gap cannot start Phase I now and close it. Licensing a later-stage asset is the only route that fits the clock (analysis).
How Big Is China’s Share of Licensing Deals?
“38% of large pharma licensing deals were originating from Chinese partners” Source: PharmExec, June 9, 2026. [8]
The same report says Chinese deals were 30% of industry upfront payments. [8] It also says the average upfront for a China-sourced deal rose from $52 million in 2022 to $172 million in early 2026. [8]
Why Do the China Deal Figures Disagree?
Source
Metric
Value
PharmExec [8]
Share of large-pharma licensing deals from Chinese partners
38%
Jefferies, via BioWorld [10]
China share of global out-licensing deals, H1 2025
32%
Pharmcube, via KrASIA [11]
China out-licensing value, 2025
$135.7 billion
SS&C Intralinks [9]
China-related transaction value, 2025
$138.8 billion of $275.1 billion global
The sources count different things. One measures deal share, one measures value. One covers large pharma, one covers all buyers. One covers half a year. Check each definition before you quote a number (analysis). SS&C also reports that license-in deals fell from 142 in 2021 to 45 in 2025, while outbound licensing reached 158 deals. [9]
How Is a Pharma Licensing Deal Structured?
The Certainty Ladder: An Original Five-Layer Framework
This is our own framework, not an industry standard. It ranks payment layers by how certain they are.
Layer
Payment type
Certainty
Example
1
Upfront cash
Paid at closing
$1.25 billion, Pfizer to 3SBio [1]
2
Non-contingent deferred cash
Fixed dates
$2 billion through 2028, BMS to BioNTech [2]
3
Development and regulatory milestones
Depends on trials and approvals
Up to $1.3 billion, Novartis to BeiGene [4]
4
Sales milestones
Depends on revenue
$250 million, Novartis to BeiGene [4]
5
Royalties
Depends on sales and patent term
High-teens to high-twenties tiers [4]
How Do Upfronts, Milestones, and Royalties Differ in Practice?
Pfizer’s deal has an upfront, milestones, and tiered double-digit royalties. [1] BioNTech expects to recognize its $3.5 billion of upfront and non-contingent cash as revenue over the BNT327 development phase. [5] It expects most milestones on approvals and during commercialization. [5]
Royalty Deal or 50/50 Co-Development: Which Structure Fits?
BMS and BioNTech chose co-development and co-commercialization with a 50/50 profit and loss split. [2] Both parties keep the right to develop BNT327 in further indications independently. [2]
Payment Mechanics: Cash Versus Equity
Akeso converted about $25.1 million of Summit’s first $300 million installment into 10 million Summit shares. [13] Summit paid the other $274.9 million in cash and owed a $200 million second installment due March 5, 2023. [13]
Territory Splits
Summit received rights in the United States, Canada, Europe, and Japan. [13] Pfizer received worldwide rights outside China. [1]
Pfizer-3SBio vs. BMS-BioNTech vs. Summit-Akeso: Three PD-(L)1 x VEGF Deals Compared
Deal
Asset
Upfront
Other fixed
Max milestones
Headline (calc.)
Upfront share (calc.)
Source
Pfizer / 3SBio, May 2025
SSGJ-707 (PD-1 x VEGF)
$1.25B
None disclosed
$4.8B
$6.05B
20.7%
[1]
BMS / BioNTech, June 2025
BNT327 (PD-L1 x VEGF-A)
$1.5B
$2.0B anniversary
$7.6B
$11.1B
13.5% (31.5% incl. fixed)
[2]
Summit / Akeso, Dec 2022
Ivonescimab (PD-1 x VEGF)
$0.5B
None disclosed
$4.5B
$5.0B
10.0%
[3]
Novartis / BeiGene, Jan 2021
Tislelizumab (anti-PD-1)
$0.65B
None disclosed
$1.55B
$2.2B
29.5%
[4]
What Does the Cluster Show?
The first three deals total $22.15 billion in headline value. Upfronts total $3.25 billion, or 14.7%. Adding BMS’s anniversary payments raises fixed cash to $5.25 billion, or 23.7% (analysis). These deals target one mechanism class. Merck’s Keytruda is a PD-1 inhibitor and faces a 2028 patent date. [12] We do not claim any buyer’s motive.
Where Does Ivonescimab Stand Now?
FDA accepted Summit’s BLA for ivonescimab in EGFR-mutated non-squamous NSCLC after TKI therapy. The PDUFA goal date is November 14, 2026. [32] That date is a regulatory goal, not an approval. Verify status before you rely on it.
How Do You Value a Pharma Licensing Deal? rNPV and the Headline Haircut
What Probability of Success Should a Model Use?
BIO analyzed 12,728 phase transitions across 9,704 programs for 2011 to 2020. [6] Overall likelihood of approval from Phase I was 7.9%. [6] Biologics reached 9.1% and new molecular entities 5.7%. [6]
Phase transition rates were 52.0% for Phase I to II, 28.9% for Phase II to III, and 57.8% for Phase III to submission. [7] Dividing 7.9% by the product of these three rates gives an implied submission-to-approval step of about 91% (analysis). That gives LOA of 52.6% from Phase III start and 15.2% from Phase II start (analysis).
Headline Haircut: Illustrative Expected Cash
Assumptions: all milestones are paid at approval. Discount rate is 10%. Pfizer-3SBio starts at Phase II and approval is five years out. BMS-BioNTech starts at Phase III and approval is four years out. Non-contingent cash is not discounted. Real schedules differ, so treat this as scale only.
Deal
LOA used
Expected milestones (undiscounted)
Fixed cash
Expected total
% of headline
Discounted total / %
Pfizer / 3SBio
15.2%
$0.73B
$1.25B
$1.98B
32.7%
$1.70B / 28.1%
BMS / BioNTech
52.6%
$4.00B
$3.5B
$7.50B
67.6%
$6.23B / 56.1%
Why Pfizer-3SBio Shrinks More
The asset was earlier. 3SBio planned its first Phase 3 study in China for 2025. [14] More of the headline sits behind a lower probability.
Why BMS-BioNTech Shrinks Less
BNT327 was already in global Phase 3 trials, and BMS owed $3.5 billion on fixed terms. [2]
Do Courts Use Probability-Weighted Value?
Yes, in damages. In a 2024 Delaware case, the court weighted each missed milestone by its probability of success and discounted it to the time of breach. [17]
How Does the IRA Change the Royalty Base?
Small molecules become eligible for Medicare negotiation seven years after approval. Biologics become eligible after 11. Negotiated prices take effect at least nine and 13 years after approval. [19] KFF reports an executive order directing HHS to work with Congress to delay small-molecule selection. [20] Check current law before you model. A lower price lowers the royalty base (analysis).
What Is the Right Royalty Rate for a Pharma License?
Royalty Ranges by Development Stage
Stage
Published range
Source
Pre-clinical
0-5%
[18]
Phase I
5-10%
[18]
Phase II
8-15%
[18]
Phase III
10-20%
[18]
Launched product
20%+
[18]
The table comes from a 2015 journal article. Use it as a floor for comparison, not as a current benchmark. [18]
What Tiers Did Novartis Agree to Pay BeiGene?
Tiered royalties ranged from the high-teens to the high-twenties of annual net sales, with customary reductions. [4] That range sits above the 2015 Phase III band for an asset already approved in China at signing. Pfizer’s agreement states only tiered double-digit royalties. [1]
What Happens to Royalties When the Patent Expires?
What Did Kimble v. Marvel Decide?
The Supreme Court decided Kimble v. Marvel on June 22, 2015. It declined to overrule Brulotte v. Thys Co., 379 U.S. 29 (1964). A contract can charge royalties only for use of the invention before the patent term ends. [21] Marvel had agreed to pay a lump sum and a 3% royalty. [21]
The Court said parties may defer payments for pre-expiration use. They may also tie royalties to non-patent rights or use non-royalty arrangements. [21]
Scenario: What a 12-Year Royalty Term Costs When the Patent Ends in Year 8
Assume $2.0 billion in annual net sales and a 15% royalty. That is $300 million a year. If the term is 12 years from launch and the last licensed patent expires in year 8, four years of royalties are at risk. That is $1.2 billion nominal. This is a hypothetical, not a real deal.
Drafting Options That Fit the Rule
Counsel can tie a lower post-expiry rate to licensed know-how or other non-patent rights, since the Court left such ties open. [21] Counsel should confirm the structure against the facts.
Who Owns the Patent You Are Licensing? Chain of Title and Bayh-Dole
What Did Stanford v. Roche Teach Licensees?
An inventor signed “agree to assign” language with Stanford. He later signed “do hereby assign” language with Cetus. Roche then acquired Cetus’s PCR assets. [22] The Supreme Court held on June 6, 2011 that the Bayh-Dole Act does not automatically vest title in a federal contractor. [22] The lesson is practical. Assignment wording in inventor agreements decides who can license (analysis).
Diligence Checklist: Verify Before You Sign
Check
Where to verify
Assignment wording from every inventor
USPTO assignment records, inventor agreements
Federal funding and Bayh-Dole status
Grant records, university disclosures
Listed patents and expiry dates
FDA Orange Book or Purple Book
Challenges and litigation
PTAB records, court dockets
DrugPatentWatch indexes Orange Book listings, Paragraph IV filings, and litigation records in one place. A team can use it to build the expiry timeline fast, then confirm each date in the FDA, USPTO, or court record. See also our guides on how to check whether a drug patent has been licensed and rNPV valuation.
Can a Licensee Challenge the Licensed Patent? MedImmune v. Genentech
What Did the Court Hold?
In 2007 the Supreme Court held 8-1 that a licensee who keeps paying royalties can still seek a declaratory judgment of invalidity. [23] MedImmune did not have to breach or end its license for Synagis. [23]
What Does It Mean for Royalty Terms?
Under a typical license, the royalty duty continues until a court declares the patent invalid. [24] The Court left open whether a patentee may treat the filing as an anticipatory breach. [24] Licensors should address challenge rights and termination triggers in the contract (analysis).
How Do Pharma Licensing Deals End? Four Exits
An Original Taxonomy of License Exits
Exit
Trigger
Documented example
1. Portfolio or data walk-away
Licensee ends the deal
Novartis-BeiGene, 2023 [4][25]
2. Effort breach
Court finds too little effort
Delaware, 2024 [27][28]
3. Licensor insolvency
Bankruptcy rejection
Section 365(n) [29]
4. Patent challenge
Invalidity ruling
MedImmune [23]
Case Study: Novartis and BeiGene
Novartis paid $650 million upfront for tislelizumab in January 2021. [4][15] It could earn up to $1.3 billion in regulatory and $250 million in sales milestones. [4] On September 17, 2023, the parties mutually ended the license. BeiGene regained global rights with no royalty due. [25] That is about 32 months after signing (analysis).
The ociperlimab deal ended in July 2023. [15] Novartis had paid $300 million upfront. A further $600 million or $700 million was payable only on option exercise. [4] Reporting tied the end to poor results from other TIGIT programs. [26]
What Did the 2024 Delaware Efforts Cases Decide?
Two Chancery decisions found buyers breached commercially reasonable efforts duties. [17] The court awarded about $130 million in the Alexion-Syntimmune case. [27] J&J was held liable for more than $1 billion to Auris Health shareholders. [28] Both cases arose from acquisition earn-outs, not licenses. The efforts clause does the same job in a license: it ties value to the buyer’s work (analysis). Alexion’s duty ran seven years and used a similarly-situated-company benchmark. [17]
What Protects a Licensee if the Licensor Goes Bankrupt?
Section 365(n) stops a licensor from cutting off licensee rights by rejecting the license. The licensee may keep its rights as they existed before bankruptcy, for the contract term. [29] The protection does not make the licensee whole. It can also halt the licensor’s duty to maintain the IP, and an unrecorded license can be exposed under Section 544. [29]
When Does an Exclusive License Need an HSR Filing?
The “All Commercially Significant Rights” Test
An exclusive pharma patent license that transfers all commercially significant rights is a potential asset acquisition. The FTC rule applies even when the licensor keeps limited manufacturing rights or co-rights. [30]
What Is the 2026 Threshold?
The size-of-transaction threshold is $133.9 million for deals closing on or after February 17, 2026. [31] The new HSR form requirements took effect February 10, 2025. [31] Counsel must decide how contingent payments count.
Patent and Contract Timeline: 1964 to 2026
Date
Event
Source
1964
Brulotte v. Thys bars post-expiry patent royalties
[21]
2007
MedImmune v. Genentech: licensee may challenge without breach
[23]
2011-06-06
Stanford v. Roche decided
[22]
2013
FTC codifies pharma license HSR rule
[30]
2015-06-22
Kimble v. Marvel keeps Brulotte
[21]
2019
Mission Product v. Tempnology: rejection is breach, not rescission
[29]
2022-12
Summit-Akeso signed
[3]
2023-09-17
Novartis-BeiGene tislelizumab license ends
[25]
2024-09-04/05
Delaware efforts rulings
[28]
2025-05-19
Pfizer-3SBio announced
[1]
2026-02-17
HSR threshold rises to $133.9M
[31]
What This Means for Licensors, Licensees, and Generic Entrants
What This Means for Licensors
Price the guaranteed layers, not the headline. Push for non-contingent payments, as BioNTech did. [2] Set royalty terms to patent expiry or tie them to separate rights. [21]
What This Means for Licensees
Model expected cash, not maximum cash. Verify title and expiry first. Plan for the licensee’s own exit rights and effort duties. [17]
What This Means for Generic and Biosimilar Developers
A license is a map of a rival’s commitments. Royalty-bearing patents and Orange Book or Purple Book dates show when exclusivity is expected to end (analysis). Merck’s Keytruda compound and method patents run to December 2028 and May 2029. [12]
What Happens Next
Three items to watch. First, the FDA decision on ivonescimab, goal date November 14, 2026. [32] Second, whether more license-out deals from China keep upfronts near $172 million. [8] Third, whether Congress changes the small-molecule IRA timeline. [20] These are open events, not forecasts.
Key Takeaways
Upfronts were 10.0% to 29.5% of headline value in four documented deals (analysis).
BMS-BioNTech fixed $3.5 billion of an $11.1 billion headline. [2]
A risk-adjusted Pfizer-3SBio headline is about one-third of $6.05 billion (illustrative).
BIO puts Phase I to approval at 7.9%. [6]
Royalties cannot run past the patent for use of the invention. [21]
A licensee can challenge the patent without breaching. [23]
Exclusive pharma licenses can need HSR filings above $133.9 million. [31]
Novartis returned tislelizumab rights about 32 months after signing (analysis of [4][25]).
FAQ
What Is a Biobuck in a Pharma Licensing Deal?
It is a contingent milestone counted in the headline. BioNTech expects most BNT327 milestones on approvals and during commercialization. [5]
Why Do Published China Licensing Totals Disagree?
The sources measure share or value, large pharma or all buyers, and half-year or full-year. [8][9][10]
Can a Licensor Charge Royalties After the Patent Expires?
Not for post-expiry use of the invention. Deferred payments for earlier use and non-patent ties remain open. [21]
Must a Licensee Stop Paying to Challenge the Patent?
No. The Court held 8-1 that a licensee need not breach. [23]
Does an Exclusive Pharma License Need an HSR Filing?
It can, if it transfers all commercially significant rights and exceeds $133.9 million. [30][31]
What Happens if the Licensor Files for Bankruptcy?
The licensee can elect to keep its rights under Section 365(n), subject to limits. [29]
How Long Does Development Take Before Royalties Start?
The BIO average from Phase I to approval is 10.5 years, as reproduced in secondary reporting. [16]
Does the IRA Change Royalty Value?
It can. Negotiated prices apply about nine years after small-molecule approval and 13 years after biologic approval. [19]
What Does Commercially Reasonable Efforts Mean in Court?
In the 2024 Alexion case, it meant efforts typical of a similarly situated company on a similar product. [17]
How Can a Team Verify Patent Expiry Before Signing?
Pull the Orange Book or Purple Book entry, the patent, and the docket. DrugPatentWatch speeds the first pass. The primary record decides.
References
Pfizer Inc. (2025, May 19). Pfizer enters into exclusive licensing agreement with 3SBio. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio
BioNTech SE. (2025, June). BioNTech and Bristol Myers Squibb announce global strategic partnership for BNT327 (Form 8-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1776985/000177698525000039/0001776985-25-000039.txt
Summit Therapeutics Inc. (2022, December 6). Summit Therapeutics partners with Akeso Inc. in deal for up to $5 billion (Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1599298/000159929822000136/a2022_prx1208xivonescimaba.htm
BeiGene, Ltd. (2024). Form 10-K for fiscal year 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1651308/000165130824000014/bgne-20231231.htm
CPHI Online. (2023, February 7). Clinical development success rates and contributing factors 2011-2020 (BIO, Informa Pharma Intelligence, and QLS). https://www.cphi-online.com/whitepaper/clinical-development-success-rates-and-contributing-factors-2011-2020-download-the-report/
AhaSignals. (2026, August 19). Clinical trial probability of success: Base rates, evidence and false precision (reproducing BIO 2011-2020 transition rates). https://ahasignals.com/biotech-expectations/clinical-trial-probability-of-success/
Pharmaceutical Executive. (2026, June 9). Deepening ties: Why China is becoming big pharma’s most essential R&D partner. https://www.pharmexec.com/view/deepening-ties-why-china-becoming-big-pharma-most-essential-rd-partner
SS&C Intralinks. (n.d.). China’s pharma sector is redrawing the global deal map. https://www.intralinks.com/resources/blog/chinas-pharma-sector-redrawing-global-deal-map
BioWorld. (2025, July 22). For big pharma, China is a shopper’s dream. https://www.bioworld.com/articles/topic/214?page=32
KrASIA. (2026). Global drugmakers eye more China biotech deals after record year. https://kr-asia.com/global-drugmakers-eye-more-china-biotech-deals-after-record-year
Precision Medicine Online. (2026). Merck pushes back on oncology slowdown concerns in Q4 and full-year 2025 call. https://www.precisionmedicineonline.com/node/46201
Summit Therapeutics Inc. (2023, January 20). Summit Therapeutics closes deal with Akeso Inc. Business Wire. https://www.businesswire.com/news/home/20230120005080/en/Summit-Therapeutics-Closes-Deal-with-Akeso-Inc.-to-In-License-Breakthrough-Innovative-Bispecific-Antibody/
IPP Bureau. (2025, May 21). Pfizer inks $1.25 billion cancer antibody licensing deal with China’s 3SBio. Indian Pharma Post. https://www.indianpharmapost.com/news/lite/pfizer-inks-125-billion-cancer-antibody-licensing-deal-with-chinas-3sbio-17180
BeiGene, Ltd. (2023). Form 10-Q for the quarter ended June 30, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1651308/000165130823000127/bgne-20230630.htm
China Healthcare. (2021, May 8). Clinical trial success rates 2011-2020 (summarizing BIO key findings). https://www.cn-healthcare.com/articlewm/20210508/content-1217774.html
Quinn Emanuel Urquhart & Sullivan. (2026, January). Life sciences update: Commercially reasonable efforts in earnout cases. https://www.quinnemanuel.com/the-firm/publications/life-sciences-update-january-2026
Valuations using royalty data in the life sciences area: Focused on anticancer and cardiovascular therapies. (2015). Journal of Open Innovation: Technology, Market, and Complexity. https://jopeninnovation.springeropen.com/articles/10.1186/s40852-015-0025-5/tables/14
Akin Gump Strauss Hauer & Feld. (n.d.). The impact of the Inflation Reduction Act of 2022 on pharmaceutical innovation, patent litigation and market entry. https://www.akingump.com/en/news-insights/the-impact-of-the-inflation-reduction-act-of-2022-on-pharmaceutical-innovation-patent-litigation-and-market-entry.html
KFF. (n.d.). The effect of delaying the selection of small molecule drugs for Medicare drug price negotiation. https://www.kff.org/medicare/the-effect-of-delaying-the-selection-of-small-molecule-drugs-for-medicare-drug-price-negotiation/
Kimble v. Marvel Entertainment, LLC, 576 U.S. 446 (2015). Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/supremecourt/text/13-720
Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc., 563 U.S. 776 (2011). Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/supremecourt/text/09-1159.ZS.html
Wiggin and Dana LLP. (2007, February 1). Supreme Court rules that a licensed patent may be challenged without breaching the license. BioInsights, Issue 9. https://www.wiggin.com/?p=25647
Mondaq. (2007). Another change in US patent law: US Supreme Court rules that patent licensees may seek declaratory judgments without first breaching the license. https://webiis05.mondaq.com/unitedstates/patent/45940/another-change-in-us-patent-law-us-supreme-court-rules-that-patent-licensees-may-seek-declaratory-judgments-in-patent-license-cases-without-first-breaching-the-license
BeiGene, Ltd. (2023, September 17). Form 8-K: Termination of a material definitive agreement. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1651308/000165130823000137/bgne-20230917.htm
MedCity News. (2023, September). BeiGene, Novartis drug alliance ends; it’s their second terminated deal this year. https://medcitynews.com/2023/09/beigene-novartis-drug-alliance-ends-its-their-second-terminated-deal-this-year/
Goodwin Procter LLP. (2024, September 12). Life sciences licensing and M&A update. https://goodwinlaw.com/en/insights/publications/2024/09/alerts-lifesciences-ma-life-sciences-licensing-and-ma-update
Farella Braun + Martel LLP. (n.d.). Three steps licensees can take to protect their IP rights in bankruptcy. https://www.fbm.com/intellectual-property/publications/three-steps-licensees-can-take-to-protect-their-ip-rights-in-bankruptcy/
Torys LLP. (2013, November). FTC makes changes to HSR rules to reach more pharmaceutical licenses. https://www.torys.com/insights/publications/2013/11/ftc-makes-changes-to-hsr-rules-to-reach-more-pharmaceutical-licenses
Covington & Burling LLP. (2026, January). FTC announces 2026 update of jurisdictional and fee thresholds for HSR premerger notification filings. https://www.cov.com/news-and-insights/insights/2026/01/ftc-announces-2026-update-of-jurisdictional-and-fee-thresholds-for-hsr-premerger-notification-filings
Summit Therapeutics Inc. (2026, February 23). Summit Therapeutics reports financial results and operational progress for the fourth quarter and year ended December 31, 2025. Business Wire. https://www.businesswire.com/news/home/20260223856924/en
